

Serial No. 009/651,083

ad
cancel

triamcinolone acetonide, noscapine, ephedrine, adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, phenylephrine, phenylpropenolamine, pirbuterol, reproterol, rimeterol, terbutaline, isoetharine, tulobuterol, orciprenaline, (-)-4-amino-3,5-dichloro-a-[[[6-[-2-(2-pyridinyl)ethoxy]hexyl]-amino]methyl]benzenemethanol, amiloride, ipratropium, atropine, oxitropium, cortisone, hydrocortisone, prednisolone, aminophylline, choline theophyllinate, lysine theophyllinate, theophylline, ^{insulin}glucagon and any mixtures thereof.

Please cancel claim 20 without prejudice or disclaimer.

Please replace claim 33 with the following replacement claim 33.

2

33(Amended). A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical powder composition ^{according to claim 13} ~~which comprises microfine particles of medicament selected from the~~ group consisting of anti-allergics, bronchodilators, anti-inflammatory steroids and mixtures thereof and at least one lactose pellet having a diameter of from about 10 to about 1500 micrometers, which pellet comprises a plurality of microfine lactose particles, and wherein at least about 90% by weight of the microfine particles of lactose have a diameter of less than about 15 micrometers.

2

Please cancel claims 34 and 35 without prejudice or disclaimer.

Please replace claims 36 and 37 with the following replacement claims.

36(Amended). A pharmaceutical powder composition according to claim 22, wherein the medicament is selected from the group consisting of salmeterol xinafoate, salbutamol sulphate and fluticasone propionate.

Serial No. 009/651,083

*Q2
conced.*

37(Amended). A pharmaceutical powder composition according to claim 23, wherein the medicament is selected from the group consisting of salmeterol xinafoate, salbutamol sulphate and fluticasone propionate.
